New application of gamma-secretase activated protein gene and/or protein coded by gamma-secretase activated protein gene

Abstract

The invention relates to a novel application of gamma-secretase activated protein gene and / or protein coded by gamma-secretase activated protein gene. According to the application disclosed by the invention, by screening acute myelogenous leukemia (AML) prognosis related molecular markers, the screened gamma-secretase activated protein gene (GSAP) is closely related to the prognosis of acute myelogenous leukemia patients; the high expression of the GSAP prompts that the prognosis of the acute myelogenous leukemia patient is poor; the GSAP is related to FAB typing and cytogenetics risk stratification of an acute myelogenous leukemia patient; and the GSAP may participate in the disease progress of acute myelogenous leukemia through various ways such as PI3K-AKT, TLR and the like. The GSAP is used for preparing a treatment drug or a diagnostic reagent and a prognosis detection reagent for acute myelogenous leukemia.

Description

technical field [0001] The invention belongs to the field of biomedicine, in particular to the new application of gamma-secretase activating protein gene and / or its encoded protein. Background technique [0002] Acute myeloid leukemia (AML) is a malignant clonal disease originating from hematopoietic stem / progenitor cells, which is mainly characterized by uncontrolled proliferation, apoptosis arrest, and differentiation arrest of myeloid primitive and immature cells, thereby inhibiting normal hematopoiesis , and cause extramedullary infiltration. The pathogenesis of AML is complicated and the clinical prognosis is poor. Although combined chemotherapy can achieve complete remission (CR) in most patients, only a few special types of AML patients can survive for a long time, and most patients develop disease within 3 years after CR. Relapse, and refractory or relapse patients have poor chemotherapy effect, so individualized treatment targeting key molecules in the occurrence a...

AI Technical Summary

Problems solved by technology

The pathogenesis of AML is complicated and the clinical prognosis is poor. Although combined chemotherapy can achieve complete remission (CR) in most patients, only a few special types of AML patients can survive for a long time, and most patients develop disease within 3 years after CR. Relapse, and refractory or relapsed patients have poor chemotherapy effect, so individualized treatment targeting key molecules in the occurrence and development of AML will become the development trend of AML treatment

At present, the research on the mechanism of AML is still insufficient, and the existing molecular targeted drugs are difficult to meet the needs of clinical treatment. Therefore, mining and searching for new key pathogenic molecules and potential intervention targets in the occurrence and development of AML will provide a basis for diagnosis and treatment stratification and prognosis. Assessment provides new evidence of critical clinical importance

Images